-
公开(公告)号：EP1492821A1
公开(公告)日：2005-01-05
申请号：EP03746252.0
申请日：2003-04-08
IPC分类号： C08B30/18 , A61K33/26 , A61K31/715 , A61P7/06
CPC分类号： C08B30/18 , A61K31/715 , A61K33/26 , A61K2300/00
摘要： An iron-dextrin compound for treatment of iron deficiency anaemia comprising hydrogenated dextrin having a weight average molecular weight equal to or less than 3,000 Dalton and a number average molecular weight equal to or higher than 400 Daltons, in stable association with ferric oxyhydroxide. As the molecular weight of the dextrin must be narrow it is another important feature of the invention that the 10 % fraction of the dextrins having the highest molecular weight has an average molecular weight of less than 4500 Daltons, and that 90 % of the dextrins are having molecular weights of less than 3000 Daltons. It is further important that the 10 % fraction having the lowest molecular weight has a weight average molecular weight of 340 Daltons or more.
-
2.发明公开A PROCESS FOR PRODUCING AN IRON-DEXTRAN COMPOUND 有权VERFAHREN ZUR HERSTELLUNG EINER EISEN-DEXTRAN VERBINDUNG
公开(公告)号：EP1123103A1
公开(公告)日：2001-08-16
申请号：EP99934521.8
申请日：1999-07-29
IPC分类号： A61K31/715 , A61K31/295 , A61K47/48 , C08B37/00
CPC分类号： C08B37/0021 , A61K31/721 , A61K47/61
摘要： In a process for producing an iron-dextran compound for use in parenteral treatment of iron-deficiency in humans or animals a stable compound of desired relatively low molecular weight is obtained by using first hydrogenation and then oxidation to convert reducing terminal groups on the dextran molecules before reaction with the iron. By varying the ratio of hydrogenated groups to oxygenated groups the average molecular weight of the resulting iron-dextran compound can be varied.
摘要翻译： 在用于人或动物的铁缺乏症肠胃外处理的铁 - 葡聚糖化合物的制备方法中，通过使用第一氢化然后氧化以转化葡聚糖分子上的还原性末端基团获得所需相对低分子量的稳定化合物 在与铁反应之前。 通过改变氢化基团与氧化基团的比例，可以改变所得铁 - 葡聚糖化合物的平均分子量。
-
公开(公告)号：EP1492821B1
公开(公告)日：2006-08-02
申请号：EP03746252.0
申请日：2003-04-08
IPC分类号： C08B30/18 , A61K33/26 , A61K31/715 , A61P7/06
CPC分类号： C08B30/18 , A61K31/715 , A61K33/26 , A61K2300/00
摘要： An iron-dextrin compound for treatment of iron deficiency anaemia comprising hydrogenated dextrin having a weight average molecular weight equal to or less than 3,000 Dalton and a number average molecular weight equal to or higher than 400 Daltons, in stable association with ferric oxyhydroxide. As the molecular weight of the dextrin must be narrow it is another important feature of the invention that the 10 % fraction of the dextrins having the highest molecular weight has an average molecular weight of less than 4500 Daltons, and that 90 % of the dextrins are having molecular weights of less than 3000 Daltons. It is further important that the 10 % fraction having the lowest molecular weight has a weight average molecular weight of 340 Daltons or more.
-
4.发明公开AN IRON-DEXTRAN COMPOUND FOR USE AS A COMPONENT IN A THERAPEUTICAL COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF IRON-DEFICIENCY, A PROCESS FOR PRODUCING SAID IRON-DEXTRAN COMPOUND AND USE OF SAID COMPOUND FOR THE PREPARATION OF A PARENTERALLY ADMINISTRABLE THERAPEUTICAL COMPOSITION 有权右旋糖酐铁化合物用作组件。在治疗组合物，缺铁性治疗或PROPPHYLAXE，及其制造方法
公开(公告)号：EP1066056A1
公开(公告)日：2001-01-10
申请号：EP99908785.1
申请日：1999-03-24
IPC分类号： A61K47/48
CPC分类号： A61K47/61
摘要： An iron-dextran compound for parenteral treatment of iron-deficiency anemia comprises hydrogenated dextran having a weight average molecular weight (Mw) between 700 and 1,400 Daltons, preferably approximately 1,000 Daltons, a number average molecular weight (Mn) of 400 to 1,400 Daltons and wherein 90 % by weight of the dextran has molecular weights less than 2,700 Daltons and the Mw of the 10 % by weight fraction of the dextran having the highest molecular weights is below 3,200 Daltons, said hydrogenated dextran having been subjected to purification by membrane processes having a cut-off value between 340 and 800 Daltons, in stable association with ferric oxyhydroxide. The compound is produced by using membrane processes to eliminate dextrans of higher molecular weights than approximately 2,700 Daltons and membrane processes to remove saccharides of molecular weights below approximately 340 Daltons from hydrogenated dextran before precipitating ferric hydroxide in the presence of said dextran followed by heat treatment and purification.
-
公开(公告)号：EP1123103B1
公开(公告)日：2002-10-02
申请号：EP99934521.8
申请日：1999-07-29
IPC分类号： A61K31/715 , A61K31/295 , A61K47/48 , C08B37/00 , A61P3/02
CPC分类号： C08B37/0021 , A61K31/721 , A61K47/61
摘要： In a process for producing an iron-dextran compound for use in parenteral treatment of iron-deficiency in humans or animals a stable compound of desired relatively low molecular weight is obtained by using first hydrogenation and then oxidation to convert reducing terminal groups on the dextran molecules before reaction with the iron. By varying the ratio of hydrogenated groups to oxygenated groups the average molecular weight of the resulting iron-dextran compound can be varied.
-
6.发明公开
公开(公告)号：EP3925443A1
公开(公告)日：2021-12-22
申请号：EP21160316.2
申请日：2013-11-29
发明人： ANDREASEN, Hans Berg , CHRISTENSEN, Lars , NORDFJELD, Kim , SKYTTE, Jeppe , CLAUSEN, Christian , HOLST, Björn
IPC分类号： A01N1/02
摘要： The present invention relates to a cryoprotecting agent comprising a cryprotectant being one or more of: dextrin, dextran, isomaltooligosaccharide and derivatives thereof, cryoprotecting and cryopreserved compositions, uses thereof, and methods of cryopreservation.
-
7.发明授权AN IRON-DEXTRAN COMPOUND FOR USE AS A COMPONENT IN A THERAPEUTICAL COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF IRON-DEFICIENCY, A PROCESS FOR PRODUCING SAID IRON-DEXTRAN COMPOUND AND USE OF SAID COMPOUND FOR THE PREPARATION OF A PARENTERALLY ADMINISTRABLE THERAPEUTICAL COMPOSITION 有权右旋糖酐铁使用的化合物作为一个组件在治疗性组合物用于生产右旋糖酐铁连接及其用途用于生产肠外适用治疗制剂治疗或缺铁预防和方法。
公开(公告)号：EP1066056B2
公开(公告)日：2008-12-10
申请号：EP99908785.1
申请日：1999-03-24
CPC分类号： A61K47/61
摘要： An iron-dextran compound for parenteral treatment of iron-deficiency anemia comprises hydrogenated dextran having a weight average molecular weight (Mw) between 700 and 1,400 Daltons, preferably approximately 1,000 Daltons, a number average molecular weight (Mn) of 400 to 1,400 Daltons and wherein 90 % by weight of the dextran has molecular weights less than 2,700 Daltons and the Mw of the 10 % by weight fraction of the dextran having the highest molecular weights is below 3,200 Daltons, said hydrogenated dextran having been subjected to purification by membrane processes having a cut-off value between 340 and 800 Daltons, in stable association with ferric oxyhydroxide. The compound is produced by using membrane processes to eliminate dextrans of higher molecular weights than approximately 2,700 Daltons and membrane processes to remove saccharides of molecular weights below approximately 340 Daltons from hydrogenated dextran before precipitating ferric hydroxide in the presence of said dextran followed by heat treatment and purification.
-
8.发明授权AN IRON-DEXTRAN COMPOUND FOR USE AS A COMPONENT IN A THERAPEUTICAL COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF IRON-DEFICIENCY, A PROCESS FOR PRODUCING SAID IRON-DEXTRAN COMPOUND AND USE OF SAID COMPOUND FOR THE PREPARATION OF A PARENTERALLY ADMINISTRABLE THERAPEUTICAL COMPOSITION 有权右旋糖酐铁使用的化合物作为一个组件在治疗性组合物用于生产右旋糖酐铁连接及其用途用于生产肠外适用治疗制剂治疗或缺铁预防和方法。
公开(公告)号：EP1066056B1
公开(公告)日：2002-07-17
申请号：EP99908785.1
申请日：1999-03-24
CPC分类号： A61K47/61
摘要： An iron-dextran compound for parenteral treatment of iron-deficiency anemia comprises hydrogenated dextran having a weight average molecular weight (Mw) between 700 and 1,400 Daltons, preferably approximately 1,000 Daltons, a number average molecular weight (Mn) of 400 to 1,400 Daltons and wherein 90 % by weight of the dextran has molecular weights less than 2,700 Daltons and the Mw of the 10 % by weight fraction of the dextran having the highest molecular weights is below 3,200 Daltons, said hydrogenated dextran having been subjected to purification by membrane processes having a cut-off value between 340 and 800 Daltons, in stable association with ferric oxyhydroxide. The compound is produced by using membrane processes to eliminate dextrans of higher molecular weights than approximately 2,700 Daltons and membrane processes to remove saccharides of molecular weights below approximately 340 Daltons from hydrogenated dextran before precipitating ferric hydroxide in the presence of said dextran followed by heat treatment and purification.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.009 秒)
